Download PDF

1. Company Snapshot

1.a. Company Description

NEUCA S.A. engages in the distribution of pharmaceuticals to pharmacies and hospitals in Poland.It operates through Pharmaceutical Wholesale; Own Brands; and Outpatient Care Clinics, Clinical Trials and Telemedicine segments.The company also provides advertising and marketing services; pharmaceutical products under its own brand; clinical trial, telemedicine, agency, financial, road cargo transport, accounting and bookkeeping, software, hospital, and information technology and computer related services; and health, property, and other personal insurance products.


In addition, it operates outpatient care clinics and medical stores.The company was formerly known as Torfarm SA and changed its name to NEUCA S.A. in April 2010.NEUCA S.A. was founded in 1990 and is based in Torun, Poland.

Show Full description

1.b. Last Insights on NEU

NEUCA S.A.'s recent performance has been positively influenced by its undervaluation in the European market. According to recent reports, the company is among three stocks that could be trading below their fair value. The current market environment, characterized by cautious monetary policy and steady inflation rates, has investors seeking undervalued stocks. NEUCA S.A.'s position in this context presents a potential opportunity. No recent earnings release or share buyback information is available to further assess the company's short-term prospects. (Source: European Market: 3 Stocks That Could Be Trading Below Fair Value, 2025-11-06)

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

European Market: 3 Stocks That Could Be Trading Below Fair Value

Nov -06

Source:

Card image cap

cBrain And 2 Other Undiscovered Gems in Europe

Apr -24

Source:

Card image cap

Exploring Europe's Undiscovered Stock Gems This March 2025

Mar -25

Source:

Card image cap

SeSa And 2 Other Stocks That May Be Priced Below Estimated Value

Nov -27

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (4.46%)

6. Segments

Wholesale Distribution of Medicines

Expected Growth: 4.5%

Strong demand for healthcare services in Poland, increasing life expectancy, and a growing elderly population drive growth in wholesale medicine distribution. NEUCA S.A.'s strategic partnerships with pharmaceutical companies, efficient logistics, and a wide distribution network also contribute to the 4.5% growth rate.

Clinical Trials

Expected Growth: 3.8%

NEUCA S.A.'s 3.8% growth in Clinical Trials is driven by increasing demand for innovative treatments, expansion of clinical research in emerging markets, and advancements in digital health technologies. Additionally, growing partnerships between pharma companies and contract research organizations, as well as rising investments in rare disease research, contribute to this growth.

Medical Operator

Expected Growth: 4.2%

NEUCA S.A.'s Medical Operator segment growth of 4.2% is driven by increasing demand for healthcare services, expansion into new markets, and strategic partnerships. Additionally, investments in digital healthcare infrastructure and a growing focus on preventive care are contributing to the segment's growth.

Insurance Activities

Expected Growth: 3.5%

NEUCA S.A.'s 3.5% growth in Insurance Activities is driven by increasing demand for health and life insurance products, expansion into new markets, and strategic partnerships. Additionally, investments in digitalization and process automation have improved operational efficiency, allowing for better customer service and retention.

Manufacturer of Pharmaceuticals

Expected Growth: 4.8%

NEUCA S.A., a pharmaceutical manufacturer, exhibits 4.8% growth driven by increasing demand for generic medicines, expansion into emerging markets, and strategic partnerships. Additionally, investments in R&D and process optimization have improved operational efficiency, contributing to the company's growth momentum.

7. Detailed Products

Pharmaceutical Wholesale

NEUCA S.A. provides a wide range of pharmaceutical products to pharmacies, hospitals, and other healthcare institutions.

Logistics and Distribution

NEUCA S.A. offers logistics and distribution services to ensure timely and efficient delivery of pharmaceutical products to customers.

Marketing and Sales

NEUCA S.A. provides marketing and sales services to pharmaceutical companies, helping them to promote and sell their products.

Clinical Trials

NEUCA S.A. provides clinical trial services to pharmaceutical companies, helping them to conduct clinical trials and gather data.

Regulatory Affairs

NEUCA S.A. provides regulatory affairs services to pharmaceutical companies, helping them to comply with regulations and obtain necessary permits.

8. NEUCA S.A.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for NEUCA S.A. is moderate due to the presence of alternative products and services in the market.

Bargaining Power Of Customers

The bargaining power of customers is high due to the concentration of large clients and the availability of alternative suppliers.

Bargaining Power Of Suppliers

The bargaining power of suppliers is low due to the company's strong relationships with its suppliers and the availability of alternative suppliers.

Threat Of New Entrants

The threat of new entrants is moderate due to the presence of barriers to entry, such as high capital requirements and regulatory hurdles.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of several competitors in the market, leading to a highly competitive environment.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 34.23%
Debt Cost 5.90%
Equity Weight 65.77%
Equity Cost 5.90%
WACC 5.90%
Leverage 52.05%

11. Quality Control: NEUCA S.A. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Faes Farma

A-Score: 7.4/10

Value: 5.2

Growth: 5.9

Quality: 8.2

Yield: 8.1

Momentum: 8.0

Volatility: 9.0

1-Year Total Return ->

View Full Report
Stock-Card
Clínica Baviera

A-Score: 6.9/10

Value: 4.1

Growth: 8.2

Quality: 8.4

Yield: 7.5

Momentum: 7.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Voxel

A-Score: 6.7/10

Value: 3.6

Growth: 7.7

Quality: 6.9

Yield: 6.9

Momentum: 9.5

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Ambea

A-Score: 6.1/10

Value: 6.3

Growth: 7.7

Quality: 4.7

Yield: 3.8

Momentum: 9.0

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Synektik

A-Score: 5.9/10

Value: 1.8

Growth: 9.8

Quality: 7.5

Yield: 5.0

Momentum: 8.5

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
NEUCA

A-Score: 4.1/10

Value: 4.7

Growth: 3.9

Quality: 3.9

Yield: 3.1

Momentum: 1.5

Volatility: 7.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

818.0$

Current Price

818$

Potential

-0.00%

Expected Cash-Flows